



FORM 7

MONTHLY PROGRESS REPORT

Name of CNSX Issuer: BRISIO INNOVATIONS INC. (the "Issuer").

Trading Symbol: BZI

Number of Outstanding Listed Securities: 36,507,993

Date: January 3, 2018

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Brisio Innovations Inc. ("Brisio" or the "Issuer") is focused on the acquisition, development and marketing of software applications for mobile computing devices, including smartphones, tablets, and wearable computers.

Throughout the month of December, the Issuer remained in contact with management of Vigil Health Solutions Inc. ("Vigil"), Lite Access Technologies Inc. ("Lite Access"), ImmunoPrecise Antibodies Ltd. ("ImmunoPrecise"), and Pioneering Technologies Corp. ("Pioneering").

On December 4, 2017, the Issuer announced that Steven Vestergaard has resigned from the Board of Directors, and Mr. Kristaps Ronka was appointed to the Board of Directors effective December 1.

Kristaps Ronka is an entrepreneur, investor and advisor. Kristaps co-founded AdParlor in 2007, a Toronto-based bootstrapped company that in 4 years become the leader in handling large Facebook Ad campaigns reaching a \$100 million run rate. In 2011, Kristaps was named in Inc.'s "Top 30 under 30" most promising young entrepreneurs for disrupting the industry with a visionary approach. AdParlor was acquired in 2011.

Kristaps has since focused on advising and backing start-up companies that are solving important problems and building disruptive technologies from transportation to medicine. His extensive knowledge of business management, new technologies and his network of established contacts will be a valued contribution to the Brisio management team.

On December 20, 2017, the Issuer announced that it had granted 1,000,000 stock options to officers and directors of the Issuer. The options were granted for a period of 5 years, expiring on December 20, 2022, and each stock option will allow the holder to purchase a common share of the Company at an exercise price of \$0.23. Certain stock options will be subject to vesting restrictions.

2. Provide a general overview and discussion of the activities of management.

Management was actively engaged in all general administrative and sundry duties of the Issuer, and focused on creating strategic relationships. The Issuer also remained in contact with management of Vigil Health Solutions Inc., (“Vigil”) Lite Access Technologies Inc. (“Lite Access”), ImmunoPrecise Antibodies Ltd. (“ImmunoPrecise”), and Pioneering Technologies Corp. (“Pioneering”).

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

No new products or services were developed to completion or offered in the current reporting month.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

No products or services were discontinued in the reporting month.

5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

There have been no new relationships entered between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements, etc. in the reporting month.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

No contracts or agreements expired or were terminated between the Issuer, the Issuer’s affiliates or third parties. In addition, there were no cancellations of any previously announced financing arrangements.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets

acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

The Issuer made no significant acquisitions or dispositions during the reporting month. On occasion, the Issuer will acquire or dispose of publicly traded shares of companies. These transactions are disclosed in the Issuer's quarterly financial statements.

8. Describe the acquisition of new customers or loss of customers.

The Issuer made no significant acquisitions of new customers or loss of customers.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

There were no new developments or effects on brand names, licenses, patents, and software during the reporting month.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Apart from the change in Directors noted in section 1 hereinabove, there were no key hirings, terminations, or lay-offs during the reporting month.

11. Report on any labour disputes and resolutions of those disputes if applicable.

The Issuer was not involved in any labour disputes in the reporting month.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

During the reporting month, there were no significant legal proceedings instituted against the Issuer.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

During the reporting month, no indebtedness was incurred or repaid outside of the normal course of operations.

14. Provide details of any securities issued and options or warrants granted.

Refer to section 1 hereinabove for details of a December stock option issuance. No other common shares, stock options or share purchase warrants were issued by the Issuer or exercised in the reporting month.

15. Provide details of any loans to or by Related Persons.

There were no loans to or by Related Persons in the reporting month, although management is owed funds from the accrual of salary for cash flow management purposes.

16. Provide details of any changes in directors, officers or committee members.

Refer to section 1 hereinabove for details of the change in directors. There were no other changes in directors, officers or committee members in the reporting month.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

There are no trends, commitments, events or uncertainties known to management which could reasonably be expected to have a material effect on the Issuer's business, the Issuer's financial condition or results of operations.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated January 3, 2018.

Paul Andreola
Name of Director or Senior
Officer

(s) Paul Andreola
Signature

President, CEO and Director
Official Capacity

<i>Issuer Details</i> Name of Issuer	For Month End	Date of Report YY/MM/D
BRISIO INNOVATIONS INC.	December, 2017	2017/01/03
Issuer Address #1052 – 409 Granville Street		
City/Province/Postal Code Vancouver, British Columbia V6C 1T2	Issuer Fax No. (604) 683-7589	Issuer Telephone No. (604) 644-0072
Contact Name Paul Andreola	Contact Position President, CEO and Director	Contact Telephone No. (604) 644-0072
Contact Email Address Paul@Brisio.com	Web Site Address http://www.Brisio.com/	